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Abstract. Patients with advanced gastric cancer generally have poor overall prognosis as well as survival rate. 
Unfortunately, in the West, gastric cancer typically occurs at an advanced stage and many of these patients have tumor 
invasion into adjacent structures (International Union Against Cancer [UICC]/American Joint Committee on Cancer 
[AJCC] Stage T4). Although T4 gastric cancer patients often have peritoneal dissemination or distant metastasis, many do 
not have M1 disease and are therefore candidates for surgery with the curative intent. A multivisceral resection (MVR) or 
gastrectomy with resection of adjacent organs is needed in T4 gastric cancer patients to achieve an R0 resection that is one 
of the most powerful forecasters of gastric cancer surgery results. Spleen, distal pancreas, liver, and large intestine (mostly 
transverse colon) were the most commonly resected organs. The therapeutic choice with acceptable postoperative morbidity 
and mortality rates in locally advanced patients with gastric cancer should be gastrectomy with MVR, where complete 
resection could be realistically obtained and where metastatic involvement of the lymph node is not evident. MVR is done 
with a curative R0 resection to provide advanced gastric cancer patients with the best survival chance. It was found that 
resections involving the pancreas, transverse colon and liver were associated with increased survival rate in comparison to 
MVR with resection of other structures. It was shown that survival rate significantly decreased in patients who had 
undergone MVR without complete resection compared to those who had an R0 resection. Nevertheless, the extent of the 
surgical resection required and further advantages of MVR are disputable. 




Gastric cancer remains the world's second-largest cause of 
cancer-related death [1,2], including 10% of newly 
diagnosed cancers [2]. While gastric cancer pathogenesis 
and etiology are a prevailing research topic with no 
proven definitive mechanism to this day, many well 
described risk factors exist. Intestinal metaplasia, gastric 
adenomatous polyps, helicobacter pylori, pernicious 
anemia, giant hypertrophic gastritis (Ménétrier disease) 
and chronic atrophic gastritis are known to be associated 
with gastric cancer [3]. Unlike Western patients, Asian 
gastric cancer patients have a better prognosis due to 
earlier detection of the disease through frequent screening 
programs. The overall disease survival rate in Japan is 
over 70%. On the other hand, over two thirds of gastric 
cancers in the United States as well as in Europe are 
usually discovered with a locally advanced resectable 
disease in advanced stages, since routine gastric cancer 
screening is not recommended due to its cost. 
Consequently, a 5-year survival rate of merely 25% for 
locally advanced disease is recorded in these countries [4]. 
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Histopathology Classification 
Two major types of gastric cancer, intestinal and diffuse, 
were characterized by Laurèn in 1965. Metastasis pat-
terns differ from the two types of gastric cancer. The 
diffuse tumors show a wider spread than intestine tumors. 
Furthermore, in diffuse cases, lymphatic permeation of 
the lungs, tumors of Krukenberg and peritoneal metasta-
ses are more common. However, the liver is more com-
monly involved in the intestinal cancer type. Gastric ade-
nocarcinoma rarely reports intestinal metastases. Primary 
stomach tumors with intestinal metastases are generally 
poorly differentiated with or without ring-cell differentia-
tion of the signet and most often belong to the scirrhous 
type. These metastases rarely include the liver and are 
often associated with peritoneal seeding. There were 
three reported cases of multiple colonic metastases of 
poorly differentiated gastric adenocarcinoma presenting 
as colonic polyposis. In one case, multiple flat elevated 
lesions appeared in a rare form of gastric signet ring-cell 
cancer with metastases to the colon [5]. 
In research in determining tumor stage in gastric 
cancer, representing the most important independent 
prognostic factor, as well as for clinical practice, the 
American Joint Committee on Cancer (AJCC)/Union 
for International Cancer Control (UICC) tumor, node, 
metastasis (TNM) staging system has been used [4]. 
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Determining the prognosis is highly influenced by 
the final pathological stage that follows the curative 
surgery. In patients with pathological stages II, III and 
IV, survival rate is significantly lower [6]. 
Optimal Surgery Treatment 
The type of gastrectomy 
The most important curability factor is surgical resec-
tion [7]. The site of the primary tumor with the resection 
margin of a minimum of 5cm from the edge of the tu-
mor determines the type of gastrectomy. According to 
the Lauren classification, total gastrectomy is used to 
treat the „diffuse‟ type tumors which are likely to spread 
laterally. It might not be necessary for distal types of 
tumors in case that mapping biopsies, careful radiologi-
cal review, adequate staging, on-table Oesophago-Gas-
tro-Duodenoscopy (OGD) with or without frozen sec-
tion provide satisfactory results. Tumors of the gastric 
antrum (distal third cancers) need a subtotal (80%) gas-
trectomy, with the excision of regional lymphatic tissue 
and the division of the left gastric vein and artery. Total 
gastrectomy is performed when sub mucosal tumor 
infiltration is within 78 cm of GOJ or in case of a large 
distal third tumor. In cases of palliation or in the very 
elderly, only limited gastric resections are recom-
mended. There is no oncological advantage but in-
creased morbidity in resecting spleen and distal pan-
creas for a cancer in the distal two-third of stomach. 
Tumors of the gastric body (middle third cancers) usu-
ally need a total gastrectomy, since it depends on the 
proximal tumor margin. The stomach level that remains 
below GOJ should be at least 2cm. A 7cm margin from 
GOJ is required in serosa negative cancer cases, while 
8cm margin from GOJ is standard in serosa positive 
cancer. The surgery‟s overall goal is appropriate lym-
phadenectomy (formal D2 and posterior mediastinal, 
periesophageal nodes), adequate local clearance, as well 
as low morbidity uncomplicated anastomosis. In pa-
tients with tumors of proximal stomach located on 
greater curvature/ posterior wall of stomach close to 
splenic hilum where incidence of splenic hilar nodal 
involvement is likely to be high, splenic and hilar node 
resection are considered [6]. 
Extension of gastric resection 
T1 disease is present at >80% of gastric cancer patients 
and merely 40% of early gastric cancer are related to 
symptoms. Overall, 85% patients have lymph node me-
tastases, 65% patients present as advanced cancers (T3, 
T4), and 40% are metastatic. Since this is a locoregional 
disease, the primary surgical aim is to remove the pri-
mary tumor with clear longitudinal and circumferential 
resection margin, with resection of associated lymph 
nodes and combined organ resection as required (R0 
resection), following the restoration of intestinal and 
biliary continuity to allow adequate nutritional intake 
[6]. 
Patients with advanced gastric cancer (Fig. 1) benefit 
from curative resection and an R0 resection is mainly 
related to improved survival rate. Some researches 
claim that multivisceral resection (MVR) can be done in 
adequately selected patients with acceptable morbidity 
and mortality. The most frequently resected organs were 
liver, distal pancreas, spleen, and large bowel (mostly 
transverse colon). Other frequently resected organs in-
cluded gallbladder and small bowel. The organs that 
were less frequently resected were adrenal gland, dia-
phragm, pericardium, mesocolon, kidney, lung, ovary 
and uterus. In gastrectomy patients with MVR, the peri-
operative mortality rates were from 1.9 to 15.0%, with 
five-year survival rates of 0–40%. These researches 
were done with the aim to identify predictors of long-
term survival, including the number of resected organs, 
UICC/AJCC stage, margin positivity and other factors, 
which may play a role in adequate patient selection for 
MVR. In order to provide patients with advanced gastric 
cancer the best chance at survival with a curative R0 
resection, MVR is performed. Survival rate in MVR 
without a complete resection patients was shown to be 
significantly lower in comparison to those who under-
went an R0 resection. Poor outcomes appear to be 
linked to both microscopic and macroscopic positive 
margins [8]. 
Despite the fact that a retrieval of a minimum of 16 
lymph nodes and a surgical R0 resection are mandatory 
surgical principles, there is still some polemics on lym-
phadenectomy and the extent of surgical resection. The 
primary tumor removal is based on the location, exten-
sion and histologic subtype of gastric cancer [4]. R0 
resection (negative microscopic and macroscopic mar-
gins) is a powerful forecaster of outcome for curative 
gastric cancer surgery patients. Unfortunately, gastric 
cancer is generally found at an advanced stage, and 
tumor invasion into adjacent structures (International 
Union Against Cancer [UICC]/American Joint Com-
mittee on Cancer [AJCC] Stage T4) is present in most 
of the patients in the West. 
Even though T4 gastric cancer patients will often 
show peritoneal dissemination or distant metastases, 
 
Fig. 1 Intraoperative view of advanced gastric cancer 
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many of them do not have M1 disease, which makes 
them suitable candidates for the surgery with the cura-
tive intent. A MVR, or gastrectomy with resection of 
adjacent organs is needed to achieve an R0 resection in 
patients with T4 gastric cancer [8]. On the other hand, 
many patients suffer from the incurable, advanced stage 
gastric cancer. The primary objective of palliative re-
section for this type of patients is relief of symptoms 
such as tumor bleeding, obstruction, or perforation. 
Studies have shown that surgical resection for stage IV 
gastric cancer can be done with low operative mortality 
and acceptable morbidity rates. It also provides good 
symptomatic relief for the patient [7].  
Treating patients who are at stage IV disease in-
cludes the following: systemic chemotherapy, surgical 
bypass procedures, palliative resection, endoscopic in-
terventions, investigational therapies, or best supportive 
care. Only modest survival rates have been recorded in 
patients treated with best supportive care alone. Pallia-
tive resection for stage IV gastric cancer is nowadays 
not a standard part of care, even though it was practiced 
regularly in the past. Certain previous researches have 
shown a benefit to the stage IV gastric cancer patient in 
case of palliative resection. On the other hand, palliative 
resection also brings the risk of surgical morbidity and 
prolonged hospitalization. This might reduce instead of 
improve the quality of life and survival rate of this type 
of cancer patients [9]. 
At the moment, the general opinion is that “a proxi-
mal margin of at least 3 cm is recommended for T2 or 
deeper tumors with an expansive growth pattern and 5 
cm is recommended for those with infiltrative growth 
pattern”, which puts an end to a long-term dispute. 
However, in T4 cases, a MVR (MVR), or gastrectomy 
with resection of adjacent organs is sometimes needed 
to provide patients with advanced gastric cancer the best 
survival chance with a curative R0 resection, but the 
prognostic benefit of MVR in patients with locally ad-
vanced disease and the postoperative morbidity are still 
under debate [4]. Kasakura et al. [10] found a higher 
complication rate in MVR group in comparison to gas-
trectomy alone group, with no difference in survival 
rates. Pacelli et al. found in their Italian multicenter 
observational study no important differences in mortal-
ity rates and postoperative morbidity [11]. Other re-
searches show a survival disadvantage for gastrectomy 
with additional organ resection. On the contrary, most 
researchers found an overall 5-year survival improve-
ment (19.9%e38%) for gastrectomy with MVRs patients 
when compared with gastrectomy or palliative surgery 
patients. In patients with T4 gastric cancer undergoing 
curative R0 resection, the 5-year survival rate ranges 
from 23% to 46%. It decreases in cases of R+ resection, 
ranging from 17.5% to 0%. Colectomy, splenectomy, 
pancreatosplenectomy, or any other organ resection did 
not forecast poor survival. In locally advanced gastric 
cancer patients where a complete resection could be 
realistically obtained and when lymph node metastatic 
involvement is not evident, the gastrectomy with MVR 
should be the therapeutic choice, with an acceptable 
postoperative morbidity and mortality rates (4). Even 
though radical resection has been found to be closely 
connected to long-term survival for gastric cancer pa-
tients, curative resection for locally advanced gastric 
cancer, defined as T4 in which the tumor invades adja-
cent structures (T4b) or perforates serosa (T4a) was 
related to increased postoperative morbidity and mor-
tality. Due to early detection of gastric cancer and im-
proved surgical technique, the gastric cancer patients‟ 
prognosis has significantly improved. On the other 
hand, T4 gastric carcinoma patients‟ prognosis re-
mained poor. It is therefore paramount to clarify the 
incidence of postoperative morbidity and mortality in 
patients with T4 gastric cancer who opt for curative 
surgeries and to determine the prognostic factors in 
these populations [12]. Gastrectomy with D2 lymphad-
enectomy (resection of perigastric lymph nodes and 
nodes along the named branches of the celiac axis) is 
considered standard surgical procedure for the advanced 
gastric cancer and most early-stage gastric cancers [3]. 
The extent of gastrectomy 
The extent of gastrectomy being performed (i.e. total, 
subtotal/distal, or proximal gastrectomy) defines the 
extent of lymphadenectomy. Most commonly, a D2 
dissection for a total gastrectomy would involve re-
trieval of lymph node stations 1-12 with a concomitant 
distal pancreatectomy and splenectomy. Moreover, a D1 
dissection would require the perigastric nodes at sta-
tions. Lately, a modified approach to a D2 dissection by 
sparing the spleen and pancreas unless directly involved 
with the primary tumor was proposed. This technique of 
sparing the spleen and pancreas has shown adequate 
retrieval of lymph nodes without the morbidity associ-
ated with multi-visceral resection (3). 
D1 lymphadenectomy happens when all N1 nodes 
(perigastric nodes closest to primary) are removed en 
bloc with the stomach (limited). D2 includes systemati-
cal removal of all N1 and N2 (distant perigastric nodes 
and nodes along main arteries supplying stomach) en 
bloc with stomach. Figure 2. Gastric cancer often re-
mained localized to stomach and adjacent lymph node. 
This supports the Japanese view that radical systemic 
D2 lymphadenectomy has increased survival benefits. 
The present European description of D2 lymphadenec-
tomy includes the removal of >15 lymph nodes, irre-
spective of node stations. Moreover, extended D3 lym-
phadenectomy represents a radical en bloc resection 
with N3 nodes outside normal lymphatic pathways from 
stomach, included in advanced stages station (hepato-
duodenal ligament) or by retrograde lymphatic flow due 
to blockage of normal pathways [8]. The Japanese re-
searchers have supported the claim that D2 resection 
should be used in all patients with invasive gastric car-
cinoma, including early gastric cancer patients. They 
also argued that a D3 lymphadenectomy should be per-
formed in all patients with advanced gastric cancer with 
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serosal invasion [1]. Two independent factors associated 
with survival were total lymph node count and number 
of positive lymph nodes. In patients who had more than 
15 N2 nodes and 20 N3 nodes examined, a significant 
survival benefit was recorded. The pathologic assess-
ment of at least 15 nodes is considered standard of care. 
Also, D2 lymphadenectomy is recommended, even 
though there is no general rule on the level of dissection 
required (D1 vs. D2) in the U.S. Higher post-operative 
mortality (13% vs. 6.5%, P=0.04) was shown in one of 
the Western studies and morbidity rates (46% vs. 28%, 
P<0.01) in the D2 lymphadenectomy group. There was 
a higher chance of undergoing concomitant pancreatec-
tomy and splenectomy. Anastomotic complications in 
the D2 dissection group have shown significantly higher 
rates, also including severe pancreatic fistula, pancreati-
tis, and gastric remnant necrosis. There was no differ-
ence in overall survival, gastric cancer related deaths, or 
recurrence-free survival in long-term results. On the 
other hand, recent studies from the East and West indi-
cate improved morbidity and mortality if routine sple-
nectomy and pancreatectomy is avoided, in comparison 
to traditional D2 resection [3]. Cuschieri et al. [13] 
evaluated 400 patients randomized to a D1 or D2 lym-
phadenectomy and found a significant survival differ-
ence between patients with gastrectomy and splenec-
tomy or pancreaticosplenectomy compared to gastrec-
tomy alone, with no regard to the extent of lymphade-
nectomy. 
Survival and Complication 
When it comes to locally advanced gastric cancer, par-
ticularly if the adjacent organ is invaded (T4), the prog-
nosis will be poor since a high incidence of postopera-
tive morbidity and mortality is reported in studies, and 
the curative resection itself is difficult [1]. For many 
years, the benefits of extended organ resection for ad-
vanced gastric cancer have been discussed. This debate 
was recently sparked by the results of both the United 
Kingdom Medical Research Council and the Dutch 
trials evaluating the survival benefit of extended lym-
phadenectomy. A significant survival disadvantage in 
patients who have undergone gastrectomy with sple-
nectomy or pancreaticosplenectomy was reported by 
both of these randomized control trials. The Medical 
Research Council study and the Dutch trial found that a 
higher complication rate, higher mortality and longer 
hospital stay are closely related to extended organ re-
section. The potential advantage of extended resection 
for clinical T4N0 gastric adenocarcinoma is necessary 
to improve the R0 resection rate of these lesions. The 
observed increase in the morbidity and mortality rates, 
with low survival benefits fuel the arguments against 
this approach. In patients undergoing gastrectomy alone, 
the complication rates of additional organ resection with 
gastrectomy have been reported to be high. When it 
comes to patients undergoing splenectomy, both overall 
complications and infectious complications have been 
reported. The increase in overall complications and 
infectious complications is the suggested reason for the 
decrease in overall survival. This is why performing 
additional organ resection in patients with T4 disease 
has been scrutinized. With minimal perioperative mor-
tality (4%), gastrectomy with additional organ resection 
for gastric cancer can be realized. In this patient subset, 
long-term survival can be reached, with a 3-year sur-
vival rate of 47%. The biology of the primary lesion 
(i.e., depth of invasion and nodal stage) might forecast 
overall survival in this patient group. Gastrectomy with 
additional organ resection can be done with low mortal-
ity and acceptable morbidity if careful patient selection 
is implemented. In order to minimize unnecessary organ 
resections for early-stage disease, certain improvements 
should be made in preoperative evaluation to confirm 
T3 and T4 disease. The most powerful forecasters of 
survival following an R0 resection are depth of invasion 
and presence and extent of lymph node metastasis. With 
the understanding that the majority will be T3, gastrec-
tomy with additional organ resection should be limited 
to clinically T4 tumors [14]. 
It cannot be said with certainty that gastrectomy 
alone, when yielding an R1 or R2 margin, is appropriate 
when R0 resection with MVR is feasible and safe. Just a 
few studies examined survival in relation to the type of 
organs resected. On the other hand, resections involving 
the transverse colon and the liver have been shown to be 
related to the increased survival compared to MVR with 
resection of other adjacent structures. The aim of R0 
resection must take into account whether gastric cancer 
 
Fig. 2 Lymphadenectomy range depending on the 
localisation of the gastric cancer 
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is actually invading adjacent organs. MVR should be 
reserved for T4 lesions, with true histological invasion 
into adjacent organs, given the risk of morbidity. Adhe-
sions secondary to desmoplastic reaction can resemble a 
local invasion, especially when the pancreas is involved. 
MVR might include resection of two or more organs in 
pursuit of negative margins. Four studies studied the 
number of organs involved or resected as a survival 
forecaster. Also, Martin et al. found an increase in oper-
ative complications with lower 5-year survival while 
comparing one-, two-, and three-organ resections in 
addition to gastrectomy [8]. 
Conclusion 
The only curative surgery for non-metastatic gastric 
cancer is surgical resection with extended lymph node 
dissection. In patients with locally advanced gastric 
cancer with the goal of R0 resection, gastrectomy with 
MVR can be performed. The benefit of attaining an R0 
resection positively influences overall patient survival, 
even though morbidity and mortality may be higher. 
Nodal status and the number of organs involved must be 
taken into account when it comes to patient selection for 
MVR and an attempt to identify true histological inva-
sion before and during resection should be made. 
In locally advanced gastric cancer patients, when a 
complete resection could be realistically obtained and 
when lymph node metastatic involvement is not evident, 
the gastrectomy with MVR should be the therapeutic 
choice with acceptable postoperative morbidity and 
mortality rates. Liver, pancreas and the transverse colon 
resections have proven to be related to increased survival 
in comparison to MVR with resection of other adjacent 
structures. 
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